S S. Sridhar

700 University Avenue
Toronto, ON, Canada

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 226 publications

A New Standard in Muscle-Invasive Bladder Cancer - The End of the Cisplatin Era?

A New Standard in Muscle-Invasive Bladder Cancer - The End of the Cisplatin Era?

Journal: The New England journal of medicine

Published: July 22, 2026

TROPION-Urothelial03: a phase II/III study of datopotamab deruxtecan (Dato-DXd) for locally advanced or metastatic urothelial carcinoma.

TROPION-Urothelial03: a phase II/III study of datopotamab deruxtecan (Dato-DXd) for locally advanced or metastatic urothelial carcinoma.

Journal: Future oncology (London, England)

Published: May 16, 2026

Re: Neoadjuvant Sacituzumab Govitecan plus Pembrolizumab, Followed by Adjuvant Pembrolizumab, in Patients with Muscle-invasive Bladder Cancer (SURE-02): A Single-arm, Phase 2 Study.

Re: Neoadjuvant Sacituzumab Govitecan plus Pembrolizumab, Followed by Adjuvant Pembrolizumab, in Patients with Muscle-invasive Bladder Cancer (SURE-02): A Single-arm, Phase 2 Study.

Journal: European urology

Published: May 05, 2026

How enfortumab vedotin plus pembrolizumab affects the quality of life of people with advanced urothelial cancer compared with platinum-based chemotherapy: a plain language summary of patient-reported outcomes from the EV-302 study.

How enfortumab vedotin plus pembrolizumab affects the quality of life of people with advanced urothelial cancer compared with platinum-based chemotherapy: a plain language summary of patient-reported outcomes from the EV-302 study.

Journal: Future oncology (London, England)

Published: April 02, 2026

Long-Term Outcomes of Neoadjuvant Chemotherapy (NAC) Prior to Bladder-Sparing Trimodality Therapy (TMT) for Patients With Muscle-Invasive Bladder Cancer (MIBC).

Long-Term Outcomes of Neoadjuvant Chemotherapy (NAC) Prior to Bladder-Sparing Trimodality Therapy (TMT) for Patients With Muscle-Invasive Bladder Cancer (MIBC).

Journal: Clinical genitourinary cancer

Published: March 30, 2026

A Silent Gap: Underrepresentation of Latin American Patients in Pivotal Genitourinary and Skin Cancer Trials.

A Silent Gap: Underrepresentation of Latin American Patients in Pivotal Genitourinary and Skin Cancer Trials.

Journal: The oncologist

Published: March 10, 2026

Addition of immune checkpoint inhibitors to intravesical BCG for high-risk BCG-naïve non-muscle invasive bladder cancer: Systematic review and meta-analysis.

Addition of immune checkpoint inhibitors to intravesical BCG for high-risk BCG-naïve non-muscle invasive bladder cancer: Systematic review and meta-analysis.

Journal: BJUI compass

Published: January 02, 2026

Expert opinion on the management of anemia in prostate cancer patients receiving PARP inhibitors.

Expert opinion on the management of anemia in prostate cancer patients receiving PARP inhibitors.

Journal: Canadian Urological Association journal = Journal de l'Association des urologues du Canada

Published: December 15, 2025

Prospective multicenter study of ctDNA versus tumor tissue guiding FGFR-targeted therapy in metastatic urothelial cancer.

Prospective multicenter study of ctDNA versus tumor tissue guiding FGFR-targeted therapy in metastatic urothelial cancer.

Journal: Nature communications

Published: October 09, 2025

Advanced Urologic Cancer Consensus Conference (AUC3) 2025: Expert consensus on the management of renal cell and urinary tract cancers.

Advanced Urologic Cancer Consensus Conference (AUC3) 2025: Expert consensus on the management of renal cell and urinary tract cancers.

Journal: CA: a cancer journal for clinicians

Published: September 15, 2025

A population-based analysis of patterns of care in patients with de novo muscle-invasive bladder cancer from Alberta, Canada.

A population-based analysis of patterns of care in patients with de novo muscle-invasive bladder cancer from Alberta, Canada.

Journal: Canadian Urological Association journal = Journal de l'Association des urologues du Canada

Published: September 02, 2025

2025 Canadian Urological Association-Canadian Uro-oncology Group Guideline: Metastatic castration-resistant prostate cancer (Update).

2025 Canadian Urological Association-Canadian Uro-oncology Group Guideline: Metastatic castration-resistant prostate cancer (Update).

Journal: Canadian Urological Association journal = Journal de l'Association des urologues du Canada

Published: August 06, 2025

Showing 1-12 of 226

Last Updated: 09/26/2026